Use of rapid response team in hospital not linked with reduction in cardio arrests or deaths
A new comprehensive online resource listing national expertise in the design and conduct of clinical trials is launched today. The UKCRC Registered Clinical Trials Units website provides, for the first time, centralised information on Clinical Trials Units (CTUs) in the UK - including the Bristol Randomised Trials Collaboration (BRTC) at the University of Bristol.
Full Post: New signpost to clinical trial expertise
Although there is an effort to implement rapid response teams in hospitals throughout the country, new research suggests that they do not result in a reduced rate of cardiopulmonary arrests or deaths, according to a study in the December 3 issue of JAMA, the Journal of the American Medical Association.
Previous studies have found that patients often exhibit physiological deterioration hours before cardiopulmonary arrest. A rapid response team, also known as a medical emergency team, is a multidisciplinary team of intensive care unit (ICU) professionals charged with the evaluation, triage, and treatment of non-ICU patients with signs of clinical deterioration to reduce the rates of in-hospital cardiopulmonary arrests (codes) and the subsequent illness or deaths that follow. The Institute for Healthcare Improvement has recommended that hospitals implement rapid response teams as 1 of 6 strategies to reduce preventable in-hospital deaths. In response, hundreds of hospitals around the country have invested significant financial and personnel resources in implementing rapid response teams, despite limited published data supporting their effectiveness, according to background information in the article.
Paul S. Chan, M.D., M.Sc., of the Mid America Heart Institute and University of Missouri, Kansas City, and colleagues examined the association between a rapid response team intervention and long-term changes in hospital-wide cardiopulmonary arrest and mortality rates. The study included adult inpatients admitted between January 2004 and August 2007 at a 404-bed tertiary care academic hospital in Kansas City. Rapid response team education and program rollout occurred from September 1 to December 31, 2005. A total of 24,193 patient admissions were evaluated prior to the intervention (January 1, 2004 to August 31, 2005), and 24,978 admissions were evaluated after the intervention (January 1, 2006 to August 31, 2007).
During the 20-month period after intervention implementation, there were a total of 376 rapid response team activations. The most common reasons for rapid response team activation were altered neurological status, tachycardia (abnormally rapid heartbeat) exceeding 130 beats per minute, tachypnea (abnormally rapid breathing) exceeding 30 breaths per minute, and hypotension (abnormally low blood pressure) assessed as blood pressure lower than 90 mm Hg.
Hospital-wide code rates per 1,000 admissions were 11.2 before rapid response team intervention and 7.5 after rapid response team intervention. This was not associated with a reduction in the primary outcome measure of hospital-wide code rates, with decreases in non-ICU code rates accounting for the majority of this difference.
Case fatality rates after cardiopulmonary arrest were similar prior to and after the rapid response team intervention (77.9 percent vs. 76.1 percent). Hospital-wide mortality rates did not meaningfully change after the rapid response team intervention (3.22 preintervention vs. 3.09 postintervention per 100 admissions). Secondary analyses revealed few instances of rapid response team undertreatment or underuse that may have affected the mortality findings.
“We believe that this study provides important new insights regarding the effectiveness and limitations of rapid response team intervention and raises critical questions about whether recommendations to disseminate rapid response teams nationally are warranted without a demonstrable mortality benefit,” the authors write.
Hospital admissions for lung cancer remained relatively stable - at roughly 150,000 a year between 1995 and 2006 - despite a steady decline in the number of Americans diagnosed with the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. Admissions have remained constant, in part, because lung
Full Post: Hospital admissions for lung cancer stable
ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the ZOLL R Series Code-Ready clinical defibrillator with a WiFi option that allows wireless communication between the defibrillator and standard hospital networks to help ensure code-readiness and download
Full Post: ZOLL Medical cleared to market defibrillator with WiFi option
The United States ranked 29th in the world in infant mortality in 2004, compared to 27th in 2000, 23rd in 1990 and 12th in 1960, according to a new report from CDC’s National Center for Health Statistics. The U.S. infant mortality rate was 6.78 infant deaths per 1,000 live births in 2004, the latest
Full Post: New U.S. infant mortality data released
According to the latest information cancer is on the increase in Australia. In a report by the Australian Institute of Health and Welfare on cancer statistics for 2008 new cancer cases are expected to increase by over 3,000 cases per year. The report shows that the number of new cancer cases diagnosed in Australia each
Full Post: Cancer is on the increase in Australia
Improved treatments for acid reflux disease, ulcers, arthritis and other conditions helped reduce hospital admission rates for internal bleeding in the upper gastrointestinal tract by 14 percent from 1998 to 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The upper gastrointestinal, or “G.I.” tract extends from the
Full Post: Fewer hospitalizations for bleeding in digestive system